News

• 07/09/2023

  ARECOR ANNOUNCES POSITIVE PRE-IND MEETING WITH FDA FOR NOVEL READY-TO-USE MEDICINE AT307 LICENSED TO HIKMA

  ↓ DOWNLOAD PDF
• 04/09/2023

  TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE

  ↓ DOWNLOAD PDF
• 17/08/2023

  ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY

  ↓ DOWNLOAD PDF
• 05/07/2023

  ARECOR ANNOUNCES ADDITIONAL AGREEMENT WITH LEADING BIOPHARMACEUTICAL COMPANY

  ↓ DOWNLOAD PDF
• 26/06/2023

  ARECOR PRESENTS POSITIVE DATA FROM US PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DELIVERED VIA INSULIN PUMP AT ADA ANNUAL MEETING

  ↓ DOWNLOAD PDF
• 27/06/2023

  ARECOR GRANTED KEY PATENTS IN EUROPE AND CHINA TO PROTECT PROPRIETARY INSULIN PRODUCTS

  ↓ DOWNLOAD PDF
• 15/05/2023

  TETRIS PHARMA LAUNCHES OGLUO® IN DENMARK AND NORWAY

  ↓ DOWNLOAD PDF
• 26/04/2023

  US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES

  ↓ DOWNLOAD PDF
• 05/04/2023

  ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER

  ↓ DOWNLOAD PDF
• 12/03/2023

  ARECOR FEATURED IN THE MAIL ON SUNDAY’S MIDAS COLUMN

  ↓ DOWNLOAD PDF
• 22/03/2023

  FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278

  ↓ DOWNLOAD PDF
• 16/02/2023

  ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS

  ↓ DOWNLOAD PDF
• 14/02/2023

  ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT

  ↓ DOWNLOAD PDF
• 30/01/2023

  ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE

  ↓ DOWNLOAD PDF
• 12/01/2023

  ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA

  ↓ DOWNLOAD PDF
• 04/01/2023

  TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA

  ↓ DOWNLOAD PDF